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Abstract
Background: Tumour associated antigens on the surface of tumour cells, such as MUC1, are being
used as specific antibody targets for immunotherapy of human malignancies. In order to address
the poor penetration of full sized monoclonal antibodies in tumours, intermediate sized antibodies
are being developed. The cost-effective and efficient production of these molecules is however
crucial for their further success as anti-cancer therapeutics. The methylotropic P. pastoris yeast
grows in cheap mineral media and is known for its short process times and the efficient production
of recombinant antibody fragments like scFvs, bivalent scFvs and Fabs.
Results: Based on the anti-MUC1 PH1 Fab, we have developed bivalent PH1 bibodies and trivalent
PH1 tribodies of intermediate molecular mass by adding PH1 scFvs to the C-terminus of the Fab
chains using flexible peptide linkers. These recombinant antibody derivatives were efficiently
expressed in both mammalian and P. pastoris cells. Stable production in NS0 cells produced 130.5
mg pure bibody and 27 mg pure tribody per litre. This high yield is achieved as a result of the high
overall purification efficiency of 77%. Expression and purification of PH1 bibodies and tribodies
from Pichia supernatant yielded predominantly correctly heterodimerised products, free of light
chain homodimers. The yeast-produced bi- and tribodies retained the same specific activity as their
mammalian-produced counterparts. Additionally, the yields of 36.8 mg pure bibody and 12 mg pure
tribody per litre supernatant make the production of these molecules in Pichia more efficient than
most other previously described trispecific or trivalent molecules produced in E. coli.
Conclusion: Bi- and tribody molecules are efficiently produced in P. pastoris. Furthermore, the
yeast produced molecules retain the same specific affinity for their antigen. These results establish
the value of P. pastoris as an efficient alternative expression system for the production of
recombinant multivalent Fab-scFv antibody derivatives.
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Background
Monoclonal antibodies (MoAbs) targeted at tumour asso-
ciated antigens (TAAs) are a promising new therapeutic
option for treating cancer patients. MoAbs such as Rituxi-
mab [1] and Trastuzumab [2] are already becoming part
of the standard treatment regimen, targeting TAA+
tumours specifically and with fewer side effects than
chemotherapeutics. However, a number of problems that
diminish antibody efficacy in a therapeutic setting still
need to be addressed. The large size of a full sized anti-
body slows vascular diffusion and prevents its penetration
deep into solid tumours[3,4]. Moreover, radionuclide or
cytotoxin coupled molecules persist longer in the general
circulation and can thus cause more toxic side-effects [5].
An equally important, yet sometimes overlooked issue is
the production of sufficient quantities of MoAb. MoAb
therapies involve high doses, usually more than 1 g per
patient per year, and can only be generated in relatively
expensive mammalian cell fermentors[6,7].
In order to address the poor tumour penetration of full-
sized antibodies, MoAb derivatives, such as Fab and scFv
fragments, have been generated that, due to their smaller
size, penetrate more readily in tissues and can deliver a
rapid peak dose at the tumour site[8]. However, mole-
cules smaller than 60 kDa are generally cleared too rapidly
from the body to allow sufficient tumour accumulation.
Intermediate sized recombinant antibodies, such as the
80 kDa minibodies, still demonstrate good tissue penetra-
tion, while not being cleared as rapidly from the blood[9-
12]. Most of these molecules lack an Fc effector domain
but can be used as blocking agents for growth factor recep-
tors, inducers of apoptosis or as carriers of radiotherapeu-
tic isotopes, toxins, cytokines or other biologically active
proteins[13-15]. Several ways of making intermediate
sized antibody derivatives have already been described
which mainly involve the usage of different dimerisation
motifs such as leucine zippers or Fc chain interactions[16-
19]. As with MoAbs, obtaining sufficient correctly folded
or heterodimerised product for large-scale application
often is a bottleneck for these recombinant antibody
derivatives. Major efforts are therefore being made in the
development of cheap and efficient heterologous expres-
sion systems. Over the last few years, yeasts, like Pichia pas-
toris, have gained a significant interest for the production
of recombinant antibody fragments using cheap mineral
defined media and requiring shorter process times as
compared to mammalian cell culture[20,21]. The possi-
bility to grow yeasts to high cell densities of up to 100 g/l
dry biomass, along with the availability of strong, induci-
ble promoters, such as the alcohol oxidase gene (AOX1)
promoter, are further advantages of heterologous expres-
sion in P. pastoris [22].
We previously described a novel model to engineer bi- or
trivalent antibody derivatives (bi- or tribodies) of inter-
mediate size (75–100 kDa), based on fusion of single-
chain variable fragments (scFv) to the C-terminus of one
or each of the Fd and L chains of a Fab fragment[23]. Fab-
scFv BsAb are efficiently produced in mammalian cells,
with 90% of the product being in the correctly het-
erodimerised form. In this study, we describe the produc-
tion and purification of the human PH1 Fab-scFv bivalent
bibody and Fab-(scFv)2 trivalent tribody directed against
the MUC1 TAA. This tumour antigen is an under-glycosi-
lated form of MUC1, and is associated with poor progno-
sis upon overexpression in breast and pancreas
cancer[24,25]. Using the Fab-sFv template, we formatted
the αMUC1 bi- and tribodies for expression in P. pastoris,
and compared the P. pastoris production system to tran-
sient expression in human HEK293T cells and stable
expression in mouse NS0 cells. The binding functionali-
ties of both mammalian and yeast derived preparations
are gauged demonstrating the functional equivalence of
the respective preparations. Combined, these results dem-
onstrate P. pastoris to be a viable alternative expression sys-
tem for Fab-scFv molecules.
Results
Construction of PH1 bibody and tribody expression vectors
The bivalent bibody and trivalent tribody targeting the
MUC1-TAA were designed using the Fab-sFv model[23]. A
bivalent bibody was generated by fusing a PH1 scFv frag-
ment to the C-terminus of the PH1 Fab Fd chain (Figure
1A). For the trivalent tribody, an additional PH1 scFv was
fused to PH1 L chain. The combination of PH1heavy-scFv
and PH1light chains (Figure 1B) leads to the formation of a
78 kDa bibody. Combining the PH1heavy-scFv and
PH1light-scFv chains results in a 104 kDa tribody.
The pES31 vector was constructed to facilitate cloning and
expression of bi- and tribody genes in mammalian cells
(Figure 1C). To this end, the βactin-βglobulin promoter
and CMV enhancer from pCAGGS were introduced in the
pCDNA3- plasmid carrying the zeocin resistance gene. To
facilitate expression and excretion, a kozak sequence and
a consensus excretion signal sequence were introduced in
front of the expression cassette. Eco47III, BspEI and
BamHI restriction sites were introduced to allow modular
exchange of antibody expression cassettes. The PH1heavy-
scFv and PH1light-scFv expression cassettes were subse-
quently cloned into pES31 for expression in HEK293T
and NS0 mammalian host cells.
For the expression of PH1 bi-and tribodies in P. pastoris, a
single vector based on pKai51 was constructed, with a
bicistronic expression cassette for both the light and heavy
chain (Figure 1D). pKai51 originated from pGAPZalfaA in
which several additional features were introduced, includ-
ing an AOX1 promotor from pPICZA. The PH1 bibody
and tribody light and heavy chains were first introduced
into separate pKai51 derived vectors, after which theBMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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Characteristics of the PH1 bi- and tribody production systems Figure 1
Characteristics of the PH1 bi- and tribody production systems. A, Schematic presentation of the assembled bibody 
and tribody molecules. Heavy chains are depicted in black, light chains in white, S-S: sulphur bond, E: E-tag (black square), H6: 
His-tag (black circle). B, Construction design for the heavy and light chain bi- and tribody expression cassettes. VH: variable 
heavy chain domain, CH1: constant heavy chain domain 1 (black). VL: variable light chain domain, CL: constant light chain domain 
(white). ss: signal sequence from BCL-1 (circle), L2: EPSGP(G4S)3 linker, L5: DVDGGSRGDGPG linker, L: (G4S)3 linker, E: E-tag 
(GAPVPYPDPLEPR) and H6: His6-tag. C, Schematic presentation of the pES31 mammalian expression plasmid carrying the 
strong βactin-βglobulin promotor. D, Schematic presentation of the pKai61 P. pastoris expression plasmid. Of note are the 
methanol induced AOX promoter and the S-tag (S) which is added to the gene insert. Also indicated (dotted line) is the place 
for gene insertion in the respective expression plasmids (C, D).BMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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expression modules for the heavy and light chain were
combined in one vector, resulting in the pKai61-BiBody-
PH1 and pKai61-TriBody-PH1 vectors.
Expression of PH1 bibody and tribody in mammalian cells
The bibody and tribody expression vectors were expressed
in the mammalian cell lines HEK293T and NS0. The
expression and heterodimeric nature of both molecules
was verified through western blot detection of reduced
and non-reduced samples with human κ and anti-His spe-
cific antibodies. Transient expression of the bibody
encoding plasmids in HEK293T cells revealed the
expected 52 and 26 kDa molecular mass bands from the
PH1heavy-scFv and PH1light chains under reducing condi-
tions and the 78 kDa bibody under non-reducing condi-
tions (Figure 2A). Similarly, transient HEK293T
expression of the tribody plasmids resulted in a 52 kDa
band from the PH1heavy-scFv and PH1light-scFv chains
under reducing conditions and the 104 kDa tribody under
non-reducing conditions (Figure 2B). The same bibody
and tribody products were obtained following stable
expression of the PH1heavy-scFv/PH1light  and PH1heavy-
scFv/PH1light-scFv plasmid combinations in NS0 cells. Fig-
ure 2C shows the western blot detection with His-tag spe-
cific antibodies of a non-reduced sample of the PH1
bibody clone NS0-Bi2. Figure 2D shows a similar blot for
Expression analysis of PH1 bi- and tribody produced in mammalian cells Figure 2
Expression analysis of PH1 bi- and tribody produced in mammalian cells. A, B, Western blot analyses of ± 1 μg 
HEK293T produced bibody (A) and tribody (B) run on a 10% SDS-PAGE gel. Gels to the left of the molecular mass ruler show 
β-mercaptoethanol reduced samples, to the right unreduced samples are shown. The bands corresponding to the respective 
antibody products are indicated by arrows and the corresponding antibody chain symbols. L: κ light chain detection, H: His 
heavy chain detection, M: relative molecular mass marker. C, D, Shown on the left is an anti-His western blot analysis of ± 20 
μl NS0 produced bibody from clone NS0-Bi2 (C) or tribody from clone NS0-Tri2 (D) supernatant. Arrows and antibody chain 
symbols indicate the running height for the respective PH1 derivatives. Shown to the right of the gels are ELISA screenings of 
culture fluid from 15 NS0-bibody (C) or NS0-tribody (D) clones on coated mGroEL-MUC1, detected with anti-κ/anti-mouse 
IgG1-AP and readout at 405 nm. Arrows show the selected clones, the horizontal black lines indicate 3× background value.BMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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the PH1 tribody clone NS0-Tri2. Both clones were selected
on the basis of ELISA with mGroEL-MUC1 coated plates
and anti-human κ detection (Figure 2C, D). Providing a
more constant long-term product supply, the stable NS0
transfectants were further used as source for mammalian
produced bi- and tribody.
Purification of mammalian cell produced PH1 bibody and 
tribody
PH1-derived bibody and tribody were purified using
immobilised metal affinity chromatography (IMAC) for
the main purification step. Figure 3A illustrates the frac-
tionation of NS0 produced PH1 tribody onto an equili-
brated IMAC column. Western blotting after elution
revealed the presence of PH1 bibody and tribody in the
200 mM imidazole fractions (Figure 3B, C). To obtain a
higher grade product, we performed SEC to remove any
remaining dimers or aggregates. To this end, 2 ml of the
eluted fraction of the bi- or tribody was loaded on a
Sephacryl S-200 column equilibrated with PBS (Figure
3D). For the bibody, the product was present exclusively
as monomers. In the tribody preparation, less than 4% of
the original sample was observed as dimers. An estimated
90% of the product loaded on the column could be recov-
ered with an estimated purity of 95%.
Based on colorimetric concentration determination and
on the analysis of the Coomassie stained SDS-PAGE gels,
the overall efficiency for stably produced PH1 bi- and tri-
body was estimated at 77% and yielded 130.5 mg bibody
and 27 mg tribody per litre NS0 supernatant, starting from
2 l cultures.
Stable production of PH1 bibody and tribody in P. pastoris
The bicistronic pKai61-BiBody-PH1 and pKai61-TriBody-
PH1 vectors were linearised and transformed to P. pastoris
through electroporation. Westernblot detection with S-
protein AP and Coomassie staining of SDS-PAGE gels
loaded with unreduced Pichia  supernatant samples
revealed the successful expression of both the PH1 bibody
(Figure 4A) and tribody (Figure 4B). As in mammalian
cells, no significant amounts of separate heavy chains
were observed during bi-and tribody expression. Expres-
sion of the PH1light-scFv light chain vector alone resulted
in production of 52 kDa free light chain monomers and
did not result in extensive light chain homodimerisation
(Figure 4C). Individual clones were screened by means of
an S-Tag assay (Figure 4D). This resulted in the selection
for further production of the bibody clone Pichia-Bi7 and
tribody clone Pichia-Tri5 which expressed the highest lev-
els of bibody and tribody.
A small scale 6 day production of the bi- and tribody was
performed in YPNM with antifoam and 1% methanol
added every 12 h. The resulting supernatant was purified
using IMAC (Figure 4E), preceded by ammonium sul-
phate precipitation to remove peptides and other interfer-
ing substances from the yeast medium. Further
purification over a gelfiltration column of the antibody
containing eluate resulted in an estimated 95% pure prep-
aration free of light chain homodimers (Figure 4F), with a
total estimated product recovery of 22%. In total 36.8 mg
pure bibody per litre of supernatant was recovered from a
250 ml shake-flask culture. For the tribody 12 mg pure
product per litre supernatant was recovered from an initial
culture volume of 500 ml.
Binding characteristics of mammalian and yeast cell 
produced bi- and tribodies
The MUC1 antigen binding capacity and apparent affinity
of PH1 bi- and tribodies, produced in NS0 and Pichia pas-
toris  cells, were verified by ELISA using recombinant
MUC1 peptide as antigen. The monovalent PH1 Fab was
used as a reference. As shown in figure 5A, the mamma-
lian produced PH1 bibody demonstrated a 25-fold
increase in apparent affinity when compared to the PH1
Fab. This increment was comparable to the values
observed for the yeast produced bibody (Figure 5B), thus
resulting in KD values of approximately 62 nM and 49 nM
for the mammalian and yeast bibody respectively. The
extra PH1 scFv attached to the PH1 tribody resulted in a
further 3-fold increase in apparent affinity in relation to
the bibody. Again, this was the case for both mammalian
(KD ≈ 20 nM; Figure 5A) and yeast cell produced (KD ≈ 12
nM; Figure 5B) tribody products. To further confirm the
equivalent binding of the NS0 and Pichia produced PH1
bi- and tribody, binding to the MUC1+ tumour cell-line
OVCAR3 was examined by flow cytometry. Both PH1
bibody and tribody demonstrated significant binding
(Figure 5C) and no apparent differences could be
observed between the mammalian and yeast expressed
products. Also, no significant binding was detected when
MUC1- Lovo cells were used (not shown). These results
demonstrate that both production methods yielded prod-
ucts with comparable specific activities.
Discussion
Alternatively glycosilated MUC1 is overexpressed on a
large number of carcinomas and is associated with poor
prognosis, making it an interesting target for antibody
immunotherapy[26-28]. The human PH1 Fab targeted
against the MUC1 TAA was used to develop a human biva-
lent bibody and trivalent tribody by respectively fusing
one or two PH1 scFvs to the C-terminus of the Fab chains.
Both molecules are of an intermediate weight, which
should slow clearing from the body compared to Fab and
scFv fragments, and should also improve tumour penetra-
tion compared to MoAbs. As with previously described
mammalian expressed bi- and tribodies[23], the
HEK293T and NS0 produced PH1 bi- and tribody wereBMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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Purification of NS0 produced PH1 bi- and tribody through IMAC and SEC Figure 3
Purification of NS0 produced PH1 bi- and tribody through IMAC and SEC. A, UV 280 nm (solid line) chromatogram 
of the serum free NS0 produced PH1 tribody, purified on a 20 ml C16/20 Chelating Sepharose Fast Flow column in 20 mM 
Phosphate buffer and eluted through an imidazole gradient (dotted line). B, C, 10% SDS-PAGE analysis of PH1 bibody (B) or 
tribody (C) IMAC fractions from NS0 culture supernatant. The left parts of the gel figures show anti-His MoAb developed 
blots with 1/1000 of a fraction loaded/lane. On the right, Coomassie stained gels are shown with 1/500 of a fraction/lane 
loaded. FT: flow through, W: Wash, F1, 2: elution fractions containing a mean of 200 and 400 mM imidazole respectively, M: 
relative molecular mass marker. The majority of the PH1 products are present in the 200 mM imidazole elution fraction. D, 
SEC purification of bi- and tribody IMAC elution fractions. UV 280 nm chromatogram of the NS0 produced PH1 bibody (solid 
line) and tribody (dotted line) purified on a C16/60 Sephacryl S-200 column. Arrows depict PH1 bibody and tribody peaks. 
Also indicated is the Bio-rad molecular mass standard run under similar conditions on the same column (black squares).BMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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expressed almost exclusively as correctly heterodimerised
Fab-scFv products, a characteristic attributed to processing
in the endoplasmatic reticulum of the L and Fd chains by
the mammalian immunoglobulin heavy chain binding
protein (BiP) chaperone [29]. However, also expression in
P. pastoris resulted in the majority of bi- and tribody prod-
ucts being correctly heterodimerised. SDS-PAGE analysis
of Pichia supernatant revealed, as in mammalian cells[23],
the absence of heavy chains released from the cells. This
suggests that the yeast Karp2, a Hsp70-class (78 kDa) heat
shock protein and analogue of mammalian BiP, plays the
same chaperone role as BiP in the endoplasmatic reticu-
lum[30,31], retaining the heavy chains until correctly
paired with a light chain. Transfection of the light chain
resulted in secretion of mainly L-chain monomers with
only a minor fraction of dimers, indicating that the affin-
ity between light chains is limited. By removing the His6-
tag sequence from the light chain DNA, L-chain
homodimers were further excluded during IMAC purifica-
tion.
In mammalian cells, the use of the strong βactin-βglobu-
lin hybrid promoter and upstream CMV enhancer in
pES31 results in increased expression compared to CMV
and EF1 promotors [32]. Transient expression of the PH1
bi- and tribody in the pES31 system produced 15.4 mg
bibody and 5.77 mg tribody per litre HEK293T medium
(not shown). These values are akin to what we described
before for mouse bispecific bibodies [32]. The three-fold
difference in expression levels between the PH1 bibody
and tribody was also observed in the stably transfected
mammalian NS0 and yeast cells. Besides the 35% larger
size of the tribody, the more complex structure of the mol-
ecule and the presence of 3 copies of both the PH1 VH and
VL could hamper the correct cellular expression.
Stable production in NS0 cells clearly resulted in
increased production compared to transient expression in
HEK293T. In addition, the use of protein free medium
raised the overall purification efficacy from 56% for
HEK293T productions to 77% for NS0 productions. The
peak cell concentration in NS0 batch culture was around
3.109 cells/l. This leaves the possibility to further increase
production by switching to a fed-batch system in which
culture conditions are more finely tuned [33]. Although
culture media costs have been significantly reduced in the
past years, producing antibodies and their derivatives in
mammalian cells still is a relatively expensive procedure
[34]. Hence, there is a profound interest in alternative pro-
duction systems based on more primitive cells with
shorter process times and the ability to grow to very high
cell densities on cheap media. The commonly used
prokaryotic E. coli expression systems do not seem suited
for the production of the large heterodimeric bi- and tri-
body molecules. Bibody production in E. coli cells resulted
in a limited expression levels of 50–250 μg product/l[35].
Pichia pastoris has however gained significant interest over
the last few years for the production of recombinant anti-
bodies and antibody fragments. This methylotropic yeast
can secrete large amounts of recombinant antibody frag-
ments like scFvs, bivalent scFvs and Fabs[20,21,36-38].
The non-human glycosilation patterns of P. pastoris are
however a problem for the production of complete
MoAbs, yet are not an issue for the non-glycosilated bi-
and tribodies. Building on this, we successfully produced
in P. pastoris PH1 bi -and tribodies in viable quantities.
Gelfiltration of the Pichia products demonstrated that very
few dimers and nearly no degradation products were
present after IMAC purification. Yet, also in P. pastoris, tri-
body clones were 3 times less productive as compared to
bibody clones. However, the surprisingly good produc-
tion level in Pichia of a trivalent antibody with 12 mg pure
product/l supernatant may be an advantage when com-
pared to other trispecific or trivalent intermediate sized
antibody models, like trispecific single chains[39,40] and
triabodies[41,42] that produce in the 0.5 mg/l range in E.
coli fermentations. Although the yields obtained in Pichia
medium were comparable to NS0 yields, the low recovery
rate from Pichia medium of 22% leaves ample room for
optimisation of the purification procedures. Replacing the
standard ammonium precipitation step, wasting about
50% of the product, with a column based capture step
may be a straightforward way to achieve such an increase
in recovery. Combined with increases in yield through
growing the Pichia clones in closely monitored fermenta-
tion conditions, further increases in overall production
yield are likely to be achieved.
Conclusion
Independent of the expression system used, the bi- or tri-
body molecules bound to their MUC1 targets with equal
effectiveness either in a peptide context or on OVCAR3
cancer cells, indicating the mammalian and yeast expres-
sion products were of similar specific activity.
Combined with the efficient expression and recovery of
the yeast produced bi- and tribodies, our results identify P.
pastoris as a valuable alternative to mammalian expression
for the production of recombinant antibody derivatives
based on the Fab heterodimerisation platform.
Methods
Anti-MUC1 antibody and antigen
The human PH1 Fab[43] and the derived PH1 scFv, both
directed against the MUC1 epitope PAPGS were a gener-
ous gift from H. Hoogenboom (Dyax, Maastricht, NL).
The MUC1 PDTRPAPGS peptide was fused to mGroEL.
This GroEL-MUC1 protein is efficiently produced in E. coli
and purified with IMAC via an N-terminal His6 tag (data
not shown).BMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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Characterisation and purification of yeast produced PH1 bi- and tribody Figure 4
Characterisation and purification of yeast produced PH1 bi- and tribody. A, B, 12.5% SDS-PAGE characterisation of 
culture supernatant from the PH1 bibody (A) or tribody (B) expressing P. pastoris cells. Left panels show S-protein-AP 
detected western blots of 100 μl samples. Right panels show Coomassie detection of 200 μl samples. C, Coomassie stained 
SDS-PAGE gel of 200 μl culture supernatant from PH1-scFv PH1 light chain expressing P. pastoris cells. Arrows and antibody 
chain symbols indicate the running height for PH1 derived proteins. M: relative molecular mass marker. D, S-tag assay for 
expression level screening of 22 Pichia pastoris bi- and tribody clones. Left graph shows results for the bibody, right graph for 
the tribody. Based on these results, bibody clone Pichia-Bi7 and tribody clone Pichia-Tri5 were selected for production. E, 
Coomassie stained 15% SDS-PAGE gel showing 1/500 samples from the IMAC elution fractions of PH1 bibody (left) and tri-
body (right) purified from ammonium precipitated Pichia supernatant. F, SEC purification of yeast produced PH1 bi- and tri-
body. UV 280 nm chromatogram of the P. pastoris produced PH1 bibody (solid line) and tribody (dotted line) purified on a 
Superdex 200 HR10/30 column. Arrows depict PH1 bibody and tribody peaks. Also indicated is the Bio-rad molecular mass 
standard run under similar conditions on the same column (black squares).BMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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Cells
HEK293T, a human embryonic kidney cell line trans-
fected with the SV40 large T-Ag (SV40TtsA1609)[44], was
used for transient eukaryotic expression. NS0 is a mouse
myeloma commonly used for hybridoma production or
stable recombinant MoAb expression. OVCAR3 cells are
derived from a human adenocarcinoma and express high
levels of MUC1-TAA. HEK293T and NS0 were grown in
DMEM medium containing 10% foetal bovine serum
(FBS). Stable NS0 clones were grown in chemically
defined hybridoma medium supplemented with synthe-
chol NS0 supplement (Sigma Aldrich, St. Lois, MO).
OVCAR3 was cultured in RPMI1640 medium supple-
mented with 10% FBS and 0.01 mg/ml bovine insulin.
Lovo is a human colorectal adenocarcinoma cell-line with
low MUC1 expression cultured in Ham's F12K with 10%
FBS. The methylotrophic yeast P. pastoris strain
GS115(his4) was obtained from Invitrogen (Merelbeke,
BE), maintained on YPD plates at 4°C and grown in liq-
uid YPD at 30°C.
Expression plasmids and gene assembly
The pES31 and pES31Hneo expression plasmids were
constructed using pCDNA3, pCDNA3.1zeo- (Invitrogen)
and the pCAGGS[45] vectors for mammalian expression.
Restriction- and DNA modifying enzymes and Vent-DNA
polymerase (New England Biolabs, Beverly, MA) were
used as recommended by the manufacturers. Gene assem-
bly was conducted by introduction of suitable restriction
sites using modifying PCR primers. All PCR-derived frag-
ments were sequence verified after cloning. The XhoI/BsaI
fragment of pCAGGS carrying the βactin-βglobulin pro-
moter and CMV enhancer was fused to the EcoRV/BsaI
fragment of pCDNA3.1-carrying the zeocin resistance
Binding characteristics of PH1 derivatives Figure 5
Binding characteristics of PH1 derivatives. A, B, ELISA on coated mGroEL-MUC1 peptide. Increasing concentrations of 
PH1 Fab (circles), bibody (squares) and tribody (triangles) purified from NS0 (A) or P. pastoris cell cultures (B) were allowed to 
interact with coated mGroEL-MUC1. After 405 nm OD readout, saturation binding curves and constants were calculated using 
non-linear regression. Shown is the mean ± SD of triplicates. C, Binding of PH1 derivatives to cell associated MUC1. Histo-
grams of flow cytometric analysis showing the interaction with MUC1+ OVCAR3 cells of the PH1 bibody and tribody from NS0 
or P. pastoris origin. Cells were stained with 20 μg/ml PH1 bibody or tribody, followed by mouse anti-human κ (filled) or anti-c-
myc IgG1 (open) isotype control MoAb. Bound MoAbs were detected with Alexa 488-conjugated anti-mouse IgG.BMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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gene. An XhoI/blunt adaptor sequence was inserted 3' of
the promoter and 5' of the pCDNA3.1-fragment. This
adaptor incorporated a kozak sequence (GCCACCATGG)
and a consensus excretion signal sequence (MGWSCIIF-
FLVATATGVHS). An Eco47III site was created in frame 3'
of the signal sequence to allow for easy insertion of genes
behind the signal sequence. At the 3' end of the gene inser-
tion point a BspeI restriction site was provided in frame
with an E-tag sequence. A BamHI site is present 3' of the
E-tag sequence in front of the stop codon when no tag is
to be attached. The pES31Hneo vector was constructed by
fusing the pES31 BspEI/BsaI fragment carrying the pro-
moter and signal sequence with the BspEI/BsaI fragment
of pCDB1E6H2sc2C11Hneo, a derivative of pCDNA3
[32]. This fragment holds a His6 tag sequence for C-termi-
nal fusion to an inserted gene and is accessible for cloning
via a BspEI site. A neomycin resistance gene is also
present.
The pKai51 yeast expression vector originated from pGAP-
ZalfaA (Invitrogen). The PCR reaction with NM743 and
NM744 (Table 1) primers introduced an N-terminal His6
tag followed by a Caspase 3 protease site to allow tag
removal. The GAP promoter was replaced with AOX1 cut
from pPICZA (Invitrogen) with a BglII/BstBI digest.
pKai51.2 was obtained through removal of the PmeI site
in the middle of the pKai51 AOX1 promoter by site-
directed mutagenesis. pKai61 originated from pKai51
through a PCR reaction with NM831 and KAI41 which
introduced an S-tag in front of the His6-tag.
Construction of the bi- and trivalent anti-MUC1 
mammalian expression vectors
Heavy and light chains of the PH1 Fab were cloned into
pES31. The Fd fragment was amplified by PCR using Vent
polymerase with primers NM265 and NM263. This PCR
fragment was BspEI cut, kinated with T4-kinase and intro-
duced into pES31Hneo, resulting in pES31-PH1heavy_neo.
The L chain was cloned in pES31 in a similar fashion using
primers NM266 and NM264, resulting in pES31-
PH1light_zeo. For the construction of the bi- and tribody
vectors, a PH1 scFv was fused to the C-terminus of the
PH1-Fd and the PH1-L chain with a flexible linker. First,
the DNA fragment coding for the flexible EPSGP(G4S)3
linker [32] was fused to the 3' end of the PH1 Fd gene with
a ApaI/PvuI digest. Similarly, the DVDGGSRGDGPG
linker [32] was fused to the 3' end of the PH1-L chain.
Next, the PH1 scFv gene was amplified using NM302 and
NM303 primers. After T4 kination, the fragment was
introduced after the linker of the PH1-Fd chain using a
BspeI digest. In this manner, the His6 tag sequence was
retained and fused to the C-terminus of the PH1 scFv,
resulting in pES31-PH1heavy-scFv_neo. For cloning the
PH1 scFv to the linker behind the PH1-L chain, a SmaI/
BamHI fragment was used. This was fused to an Eco47III/
Table 1: Primers used in this work, in order of appearance, 5' to 3' notation
Name Sequence 5' to 3'
NM743 CCCGTTAACATGGTGATGGTGATGATGCATATGAGCATGCCTTTTCTCGAGAGATACCCCTTC
NM744 CCCGGCTCGGACGAAGTGGATATCTAAGCTTGAGCTCTAACTAGTTAGCCTTAGACATGACTGTTCC
NM831 AAAAGGCATGCTAAGGAGACTGCTGCCGCCAAATTCGAGAGACAACACATGGACTCCCATATGCATCATCACCATCAC
KAI41 TCTAGGACTAGTGGATCCGCACAAACGAAGGTCTCA
NM265 CAGGTCCAGCTGGTGCAGTC
NM263 TATGGATCCTTATCCGGAGGGCCCTGCGGCCGCACAAGATTTGGGCTC
NM266 CTTGAAATTGTGCTGACTCAGTCTCC
NM264 TATGGATCCTTATCCGGAGGGCCCACACTCTCCCCTGTTGAAGCTC
NM302 AGCCCCGGGCAGGTCCAGCTGGTGCAGTC
NM303 TATGGATCCTTATCCGGATCGTTTGATATCCACTTTGGTC
NM938 AGGCTAACTAGTTTAGGCGCCACGTGGTTCCAG
NM937 AGGCTAACTAGTTTATCTTTTGATATCCACTTTGGTCCCAGBMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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PvuI fragment and a BamHI/PvuI fragment from pES31,
yielding pES31-PH1light-scFv_zeo.
Construction of antibody expressing plasmids for Pichia 
pastoris
Using the mammalian vectors, the PH1 light chain was
amplified from pES31-PH1light_zeo with NM266 and
NM938 and cloned into pKai51.2 with an EcoRV/SpeI
cut, resulting in pKai51.2-PH1light. The heavy chain PH1
was amplified from pES31PH1heavy_zeo with NM265 and
NM938 and cloned into pKai61 with a EcoRV/SpeI cut,
resulting in pKai61-PH1heavy. pKai51.2-PH1light-scFv, con-
taining the light chain PH1-scFv PH1, was made by clon-
ing the EcoRV/SpeI digested amplification fragment from
pES31-PH1light-scFv_zeo with primers NM266 and
NM937. Similarly, the PH1 heavy chain-scFv PH was
amplified from pES31-PH1heavy-scFv_neo with NM265
and NM937, cut with EcoRV/SpeI and cloned in pKai61,
resulting in pKai61-PH1heavy-scFv. Finally, vectors con-
taining 2 expression modules for the heavy and light
chain were assembled as follows: pKai61-BiBody-PH1 is
the ligation product of pKai61-PH1heavy-scFv cut with
BamHI/BsrGI and pKai51.2-PH1light cut with BglII/BsrGI.
pKai61-TriBody-PH1 is a combination of pKai61-
PH1heavy-scFv cut with BamHI/BsrGI and pKai51.2-
PH1light-scFv cut with BglII/BsrGI.
Transient Expression in HEK293T cells
For transient antibody expression, HEK293T cells were
transfected according to the Ca3(PO4)2  precipitation
method [46]. In brief, cells were seeded at 4 × 106 cells/
175 cm2, 20 h before transfection, after which 14 μg DNA
of each expression plasmid was added to the cells for 24
h. For expression of the bibody pES31-PH1heavy-scFv_neo
and pES31-PH1light_zeo were used. The tribody was
expressed by combining the pES31-PH1heavy-scFv_neo
and pES31-PH1light-scFv_zeo plasmids. The cells were
then covered with supplemented DMEM containing 5
mg/l bovine insulin, 5 mg/l transferrin and 5 μg/l sele-
nium (ITS). Medium was harvested every 48 h. For both
the bi- and tribody production, 1600 ml HEK293T super-
natant was collected.
Stable expression in NS0 cells
NS0 cells were transfected by electroporation with pES31-
PH1heavy-scFv_neo and pES31-PH1light_zeo for the
bibody, pES31-PH1heavy-scFv_neo and pES31-PH1light-
scFv_zeo for the tribody. 2.5 μg of each plasmid was used
with Nucleofector technology (Amaxa Biosystems,
Cologne, Germany) and program settings G16 and T27 in
buffer T as indicated by the manufacturer. Prior to trans-
fection, DNA was sterilised on a 0.22 μm filter. Linearised
DNA was obtained through a ScaI digest, followed by a
Wizard DNA cleanup procedure (Promega, Leiden, NL).
Control transfections were performed using 5 μg
pmaxGFP plasmid. After 24 h–48 h transfected cells were
evaluated for GFP expression and put on selective
medium containing 0.6 mg/ml G418 (Invitrogen) and/or
0.6 mg/ml zeocin (Invitrogen). Mock transfections were
performed using H2O instead of DNA. After 1 month of
selection, subclones were generated using limiting dilu-
tion. ELISAs were performed to ascertain bi- and tribody
clone production levels. The best bibody and tribody
clone were adapted to protein free hybridoma medium
and grown in roller bottles for 7 days. For each clone 3
roller bottles of 670 ml NS0 supernatant/bottle were col-
lected.
Stable expression in P. pastoris yeast cells
Prior to transformation 10 μg of the bicistronic expression
vectors pKai61-BiBody-PH1 and pKai61-BiBody-PH1
were linearised with a PmeI digest. The plasmid DNA (2.5
μg) was transformed into 100 μl competent P. pastoris
GS115 cells by electroporation using a Gene Pulser (Bio-
Rad) and 0,2 cm gap cooled electroporation cuvettes. The
electric pulse parameters were: 1500 V, 40 μF, 200 Ω and
8 ms duration. Immediately after the pulse, 1 ml of 1 M
ice-cold sorbitol was added. This mixture was transferred
to tubes containing 2 ml YPD medium. These tubes were
incubated at 30°C for 1 – 1.5 hour without shaking. 50 μl
was subsequently plated on YPD-agar plates containing
100 μg/ml zeocin and incubated at 28°C for 3–4 days.
Colonies were screened for expression through small-
scale expression experiments in 24 well deep-well plates
containing 2 ml YPNM medium. After 48 h of methanol
induction, several clones were compared by means of an
S-Tag assay. Production of the bibody and tribody was
performed in shake flasks containing 250 ml YPNM
medium/flask.
Purification
The HEK293T derived bi- and tribodies were purified
using an adaptation of a previously described protocol for
mouse bi- and tribodies [32]. Harvested mammalian
medium was centrifuged for 20 min at 13000 × g and fil-
tered over 0.22 μm bottle-top filters (Nalgene, Neerijse,
BE). Having a predicted pI of 7.9 and 8.0 respectively, the
pH of the bi -and tribody HEK293T samples was adjusted
to pH 5.5 with acetic acid before loading on a 200 ml
XK50/20 SP Sepharose Fast Flow (GE Health, Uppsala,
Sweden) cation exchange chromatography (CEC) column
equilibrated with 50 mM NaAc buffer pH 5.5 and run at 9
ml/min. Further purification of the CEC fractions was per-
formed using 1 ml Hitrap columns (GE Health) loaded
with Ni2+. The sample was supplemented with 20 mM
Imidazole pH 7.5 and pH was adjusted to 7.5. The col-
umn was equilibrated using 20 mM phosphate (PP) buff-
ers containing 0.5 M NaCl and run at 2 ml/min. For
elution 20 mM PP buffer with 200 mM or 400 mM imida-
zole and 0.5 M NaCl were used. IMAC of serum free NS0
samples was performed on a 20 ml C16/20 Chelating
Sepharose Fast Flow column (GE Health), under the sameBMC Biotechnology 2009, 9:70 http://www.biomedcentral.com/1472-6750/9/70
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buffer conditions as the 1 ml Hitrap columns, but using a
gradient elution with 20 mM PP buffer containing 500
mM imidazole and 0.5 M NaCl. For size exclusion chro-
matography (SEC), the sample was concentrated to 2 ml
using Centricon centrifugal filter devices (Amicon
Bioseperations, Beverly, MA), with a cut-off of 10 kDa.
Size exclusion chromatography was performed on a 120
ml C16/60 Sephacryl S-200 high resolution grade column
(GE Health) and run at 0.5 ml/min with PBS. The column
was calibrated before each run with Gel Filtration Stand-
ard (Bio-Rad Laboratories, Hercules, CA).
Harvested yeast medium was precipitated by addition of
70% (NH4)2SO4. After centrifugation, the pellet was dis-
solved in 10 ml 20 mM NaH2PO4, 300 mM NaCl, 20 mM
imidazole pH 7.5. This solution was injected on a 62 ml
desalting sephadex G-25 column (XK16/31) with the
same buffer. The desalted protein fraction was further
purified on a 6 ml Ni sepharose column for the bibody
and on a 1 ml HisTrap column for the tribody. The col-
umn was equilibrated with 20 mM NaH2PO4, 300 mM
NaCl, 20 mM imidazole pH 7.5, washed with 50 mM imi-
dazole and eluted by 400 mM imidazole in the same
buffer. The eluted protein fraction was finally purified by
1 ml injections on a Superdex 200 HR10/30 column to
PBS. All liquid chromatography (LC) runs were per-
formed at 4°C on Pharmacia FPLC or Akta purifier sys-
tems (GE Health).
Analysis of protein fractions
Collected protein fractions were analysed by SDS-PAGE,
after precipitation with TCA. Proteins were visualized
using Coomassie Brilliant Blue dye or Western blotted to
a nitrocellulose membrane. Immunodetection of the pro-
teins on the blot was performed by incubating consecu-
tively with mouse IgG1 anti-human κ serum, mouse IgG1
anti-human Fd serum (Sigma Aldrich, St. Louis, MO) or
mouse IgG1 anti-His (Qiagen, Venlo, NL) and alkaline
phosphatase (AP) conjugated anti-mouse IgG1 (Becton
Dickinson-Pharmingen, Erembodegem, BE). Alterna-
tively, for yeast constructs S-protein-AP (Merck, Nothing-
ham, UK) was used to detect western blots. Antibodies
were incubated for 1 h at room temperature (RT) in a solu-
tion containing 5% skimmed milk powder, 50 mM Tris
pH 8.0, 0.47% NaCl, 0.2% NP40 and 0.02% NaN3. Sub-
sequent visualisation was performed with NBT/BCIP sub-
strate 'ready to use tablets' (Roche, Vilvoorde, BE). Protein
recovery and purity were determined on Coomassie gels
that were scanned and analysed with Quantity One soft-
ware (Bio-rad). Protein concentrations of pure protein
were measured with the Micro BCA™ Protein Assay Rea-
gent Kit (Pierce, Rockford, IL) with IgG standard protein.
Concentrations of PH1 molecules from P. pastoris
medium were quantified with the FRETWorks S-tag assay
kit (Merck) according to the instructions of the manufac-
turer. Yields were calculated as: (amount of bi- or tribody
withheld in elution)/(total amount of bi- or tribody
found before the purification step). Additionally for gelfil-
trations, the purity was calculated by measuring the area
under the curve for the total run compared to the specific
bi- or tribody peak. The overall yield was calculated by
dividing the ultimate quantity of pure bi/tribody by the
estimated starting quantity before purification.
ELISA
96 well plates were coated overnight at RT with 50 μl
mGroEL-MUC1 (10 μg/ml) in NaHCO3 buffer pH 9.6.
Plates were blocked with PBS buffer + 0.05% Tween20
and 1% BSA (PBS-BSA) for 2 h at 37°C. Dilution series of
the Ab-derivatives were added in 50 μl PBS-BSA and incu-
bated for 1 h at 37°C. In between steps, plates were
washed 3 times with PBS + 0.05% Tween20. Detection
was performed by incubating consecutively with mouse
IgG1 anti-human κ serum and AP-conjugated anti-mouse
IgG1. After adding the p-nitrophenyl phosphate (PNPP)
substrate in 10% diethanolamine + 1 mM MgCl2 pH 9.8,
absorbance at 405 nm was measured in a microplate
reader (Bio-Rad). Negative controls consisted of wells
treated with antibodies but not coated with antigen and
wells that were coated and received detection antibodies,
but no samples. ELISA binding curves and KD were calcu-
lated using Prism 4.0 software (Graphpad, San Diego,
CA).
Flow cytometry
Aliquots of 2 × 105 cells were incubated with PH1 deriva-
tives in PBS + 0.5% BSA and 0.02% NaN3 (PBS-A) on ice
for 2 h. After washing, the cells were allowed to subse-
quently interact with mouse IgG1 anti-human κ and Alexa
Fluor 488-conjugated goat anti-mouse antibodies (Invit-
rogen) on ice for 1 h. Finally, the cells were resuspended
in 300 μL PBS-A. For isotype control, 10 nM 9E10 MoAb
(mouse IgG1, Becton Dickinson-Pharmingen) was used
instead of PH1 derivatives. Flow cytometric analysis was
performed using a FACScan flow cytometer (Becton Dick-
inson). Data analysis based on the collection of 10.000
events per sample was performed using WinMDI 3.7 soft-
ware (Joseph Trotter).
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